Ecor1 Capital Increased Its Position in Dicerna Pharmaceuticals Ord (DRNA) by $9.05 Million; Cvs Health (Call) (CVS) Shareholder Hap Trading Boosted Its Stake by $557,100

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Ecor1 Capital Llc increased its stake in Dicerna Pharmaceuticals Ord (DRNA) by 19.5% based on its latest 2019Q3 regulatory filing with the SEC. Ecor1 Capital Llc bought 646,571 shares as the company’s stock rose 8.52% . The institutional investor held 3.96M shares of the health care company at the end of 2019Q3, valued at $56.91M, up from 3.32 million at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Dicerna Pharmaceuticals Ord for a number of months, seems to be bullish on the $1.80B market cap company. The stock increased 0.45% or $0.12 during the last trading session, reaching $26.63. About 483,087 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 9.57% since December 8, 2018 and is uptrending. It has outperformed by 9.57% the S&P500. Some Historical DRNA News: 20/04/2018 – Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam; 08/03/2018 – DICERNA PHARMACEUTICALS INC – QTRLY SHR LOSS $0.90; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 14/05/2018 – Dicerna Pharmaceuticals 1Q Loss/Shr 30c; 20/04/2018 – ADVISORY-Alert on Dicerna, Alnylam litigation settlement wrongly coded to American Lorain; 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 20/04/2018 – DICERNA REPORTS SETTLEMENT OF ALL LITIGATION WITH ALNYLAM; 30/05/2018 – Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial; 14/05/2018 – DICERNA PHARMACEUTICALS INC – BELIEVES THAT IT HAS SUFFICIENT CASH TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 30/05/2018 – DICERNA PHARMACEUTICALS INC – EXPECTS TO HAVE CLINICAL PROOF-OF-CONCEPT DATA FROM PHYOX TRIAL IN SECOND HALF OF 2018

Hap Trading Llc increased its stake in Cvs Health Corp (Call) (CVS) by 46.17% based on its latest 2019Q3 regulatory filing with the SEC. Hap Trading Llc bought 185,700 shares as the company’s stock declined 2.55% . The institutional investor held 587,945 shares of the medical and nursing services company at the end of 2019Q3, valued at $1.94 million, up from 402,245 at the end of the previous reported quarter. Hap Trading Llc who had been investing in Cvs Health Corp (Call) for a number of months, seems to be bullish on the $98.04B market cap company. The stock increased 1.18% or $0.88 during the last trading session, reaching $75.36. About 5.10M shares traded. CVS Health Corporation (NYSE:CVS) has declined 17.14% since December 8, 2018 and is downtrending. It has underperformed by 17.14% the S&P500. Some Historical CVS News: 07/05/2018 – CVS TO BUY FRED’S ENTRUSTRX FOR $40M PLUS INVENTORY VALUE; 02/05/2018 – CVS Health Sees 2018 EPS $5.11-EPS $5.32; 11/04/2018 – CVS Health is introducing a system to provide customers with greater insight into drug costs and lesser expensive alternatives; 08/03/2018 – SnoreRx, the #1 Rated Anti Snoring Product, Sees Extraordinary Sales Success at CVS; 06/03/2018 – S&PGR Downgrades CVS Health To ‘BBB’; Debt Rated ‘BBB’; 14/03/2018 – CVS Health Corporation Announces Quarterly Dividend; 06/03/2018 – Bloomberg Markets: CVS $40 Billion Bond Sale; 11/04/2018 – CVS unveils a tool that makes it easier to find less expensive drugs; 02/05/2018 – CVS 1Q ADJ EPS $1.48, EST. $1.41; 02/05/2018 – CVS CONFIRMS 2018 FULL YEAR OUTLOOK

More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Nasdaq.com which released: “Healthcare Stocks That Hit New Highs (XBIT, DRNA, CRSP…) – Nasdaq” on November 19, 2019, also Benzinga.com with their article: “10 Biggest Price Target Changes For Monday – Benzinga” published on November 25, 2019, Benzinga.com published: “Mid-Morning Market Update: Markets Edge Lower; United Bankshares To Buy Carolina Financial – Benzinga” on November 18, 2019. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Finance.Yahoo.com and their article: “The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit’s NASH Drug – Yahoo Finance” published on November 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial – Yahoo Finance” with publication date: December 03, 2019.

Ecor1 Capital Llc, which manages about $791.89M US Long portfolio, decreased its stake in Ultragenyx Pharmaceutical Ord (NASDAQ:RARE) by 436,345 shares to 61,554 shares, valued at $2.63M in 2019Q3, according to the filing. It also reduced its holding in Argenx Adr Rep Ord by 50,000 shares in the quarter, leaving it with 531,165 shares, and cut its stake in Mirati Therapeutics Ord (NASDAQ:MRTX).

Since November 19, 2019, it had 0 insider buys, and 1 insider sale for $38.55 million activity.

Investors sentiment increased to 1.54 in 2019 Q3. Its up 0.02, from 1.52 in 2019Q2. It increased, as 10 investors sold DRNA shares while 25 reduced holdings. 29 funds opened positions while 25 raised stakes. 45.79 million shares or 1.41% more from 45.15 million shares in 2019Q2 were reported. Quantitative Systematic Strategies Ltd Liability Co owns 11,984 shares. Bancorporation Of America De reported 209,054 shares. California Employees Retirement System holds 102,675 shares. Manchester Management Limited Liability Corp has 0.03% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 18,857 shares. Spark Inv Mgmt invested 0.15% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). State Board Of Administration Of Florida Retirement Systems reported 21,334 shares. Vanguard Group has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Altrinsic Global Ltd Limited Liability Company has invested 0.06% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ubs Asset Management Americas reported 49,911 shares stake. Susquehanna Intll Gp Llp holds 0% or 26,862 shares. Marshall Wace Llp invested 0.02% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Morgan Stanley owns 19,267 shares or 0% of their US portfolio. Savings Bank Of Mellon has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Proshare Ltd Limited Liability Company holds 0% or 24,406 shares. Moreover, Artal Group Inc has 0.58% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1.00M shares.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: Seekingalpha.com which released: “CVS And The $70 Question – Seeking Alpha” on November 11, 2019, also Seekingalpha.com with their article: “Starboard Value takes stake in CVS – Dow Jones – Seeking Alpha” published on November 25, 2019, Fool.com published: “Better Buy: CVS Health vs. Walmart – The Motley Fool” on November 24, 2019. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: 247Wallst.com and their article: “Starboard Value Stake Momentarily Shakes Up CVS – 24/7 Wall St.” published on November 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “Did Hedge Funds Drop The Ball On CVS Health Corporation (CVS) ? – Yahoo Finance” with publication date: November 30, 2019.

Hap Trading Llc, which manages about $1.23B US Long portfolio, decreased its stake in Exact Sciences Corp (Call) (NASDAQ:EXAS) by 909,300 shares to 92,400 shares, valued at $111,000 in 2019Q3, according to the filing. It also reduced its holding in Medicines Co (NASDAQ:MDCO) by 98,122 shares in the quarter, leaving it with 39,078 shares, and cut its stake in Biohaven Pharmactl Hldg Co L.

Investors sentiment increased to 1.29 in Q3 2019. Its up 0.18, from 1.11 in 2019Q2. It increased, as 49 investors sold CVS shares while 420 reduced holdings. 127 funds opened positions while 480 raised stakes. 962.25 million shares or 1.42% more from 948.80 million shares in 2019Q2 were reported. Westport Asset Management has 1.26% invested in CVS Health Corporation (NYSE:CVS) for 27,792 shares. Manitoba – Canada-based Cardinal Inc has invested 1.48% in CVS Health Corporation (NYSE:CVS). Ibm Retirement Fund stated it has 0.26% of its portfolio in CVS Health Corporation (NYSE:CVS). Hilltop Hldg holds 0.42% or 35,167 shares. 132,651 are held by Pennsylvania Tru Com. 108,618 are held by Eagle Ridge Invest Mngmt. Culbertson A N Company Inc reported 1.78% of its portfolio in CVS Health Corporation (NYSE:CVS). Td Asset Mgmt owns 597,723 shares for 0.06% of their portfolio. 10,764 were accumulated by Rwc Asset Management Limited Liability Partnership. Petrus Tru Lta has 3,293 shares. Toth Advisory holds 43,955 shares. New York-based Clark Estates Inc Ny has invested 0.27% in CVS Health Corporation (NYSE:CVS). Kidder Stephen W holds 48,075 shares or 1.19% of its portfolio. Wellington Management Group Limited Liability Partnership has invested 0.58% in CVS Health Corporation (NYSE:CVS). Rodgers Brothers stated it has 23,147 shares.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart